Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

MadeMed vs Strut Health

Two GLP-1 desks, one scoreboard. We put MadeMed and Strut Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 8 · Grade B

MadeMed

Visit MadeMed Full brief →
vs
No. 18 · Grade B

Strut Health

Visit Strut Health Full brief →

The verdict

MadeMed takes this head-to-head.

MadeMed scores 86 to 84 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.

That doesn't make Strut Health a bad call — it's best for readers who want a needle-free route at the lowest tracked price and are comfortable with a recurring auto-refill. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
92
84
Supply Reliability
84
82
Transparency
94
86
Access Breadth
76
86
Clinical Oversight
84
82
Track Record
82
84
MadeMedBrief Score 86 · 84Strut Health

Price, coverage & the tracker

MadeMedStrut Health
Brief Score86/100 (B)84/100 (B)
Semaglutide$239/mo injectable · $219/mo sublingual (quarterly)$99/mo lozenge · $149/mo injectable (auto-refill)
Tirzepatide$399/mo injectable · $299/mo sublingual (quarterly)$199/mo lozenge · $199/mo injectable (auto-refill)
Coverage40 states49 states (not Alaska)
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
On the trackerStableprice stableStableprice stable

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

Strut Health: Cheapest oral route we track at $99 — but only on auto-refill; the one-off rate runs higher.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.